Livanova Plc OR Sh (LIVN)

$55.91 +1.38 (2.53%)
Market Cap 2.98B
Revenue (ttm) 1.25B
Net Income (ttm) 63.23M
EPS (ttm) N/A
PE Ratio 17.17
Forward PE 17.08
Profit Margin 5.04%
Debt to Equity Ratio 0.38
Volume 555,600
Avg Vol 679,648
Day's Range N/A - N/A
Shares Out 54.60M
Stochastic %K 39%
Beta 0.97
Analysts Strong Sell
Price Target $64.67

Company Profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy...

Industry: Medical Devices
Sector: Healthcare
Phone: 44 20 3325 0660
Address:
20 Eastbourne Terrace, London, United Kingdom
healthcareguru
healthcareguru Sep. 16 at 7:35 PM
$LIVN back to $50 👎
0 · Reply
THE_Perfusionist
THE_Perfusionist Sep. 12 at 9:36 PM
$IINN $LIVN has them beat along with other Huge player like $MDT https://www.livanova.com/cardiopulmonary/en-us/essenz/in-line-blood-monitor https://www.medtronic.com/en-us/healthcare-professionals/products/cardiovascular/extracorporeal-membrane-oxygenation/nautilus-smart-ecmo-oxygenator-module.html This disposable ECMO oxy has this tech built in! This is where the ECMO space is going. Not standalone devices.
3 · Reply
Mogeyman
Mogeyman Sep. 9 at 7:56 PM
$LIVN
0 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 12:00 PM
Needham has updated their rating for LivaNova ( $LIVN ) to Buy with a price target of 64.
0 · Reply
Mogeyman
Mogeyman Sep. 3 at 10:44 AM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 28 at 11:34 AM
$LIVN
0 · Reply
healthcareguru
healthcareguru Aug. 27 at 12:19 AM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 26 at 7:25 PM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 25 at 4:51 PM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 22 at 8:20 PM
$LIVN
0 · Reply
Latest News on LIVN
LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 4:00 PM EDT - 8 days ago

LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

LivaNova Appoints Donald Zurbay as a New Director

Sep 4, 2025, 9:00 AM EDT - 15 days ago

LivaNova Appoints Donald Zurbay as a New Director

LivaNova to Host Investor Day on November 12, 2025

Aug 25, 2025, 9:00 AM EDT - 25 days ago

LivaNova to Host Investor Day on November 12, 2025

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

Aug 22, 2025, 9:00 AM EDT - 4 weeks ago

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

LivaNova Launches Essenz Perfusion System in China

Aug 18, 2025, 9:00 AM EDT - 4 weeks ago

LivaNova Launches Essenz Perfusion System in China

LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:18 PM EDT - 6 weeks ago

LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

Aug 6, 2025, 6:00 AM EDT - 6 weeks ago

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

LivaNova to Announce Second-Quarter 2025 Results

Jul 9, 2025, 9:00 AM EDT - 2 months ago

LivaNova to Announce Second-Quarter 2025 Results

LivaNova: The Sell-Off Is Excessive Here

Jul 7, 2025, 1:34 PM EDT - 2 months ago

LivaNova: The Sell-Off Is Excessive Here

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Jun 5, 2025, 8:15 AM EDT - 3 months ago

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

Jun 5, 2025, 8:00 AM EDT - 3 months ago

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

Jun 4, 2025, 8:00 AM EDT - 3 months ago

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

LivaNova to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 8:00 AM EDT - 4 months ago

LivaNova to Present at the Jefferies Global Healthcare Conference

LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

May 11, 2025, 2:56 AM EDT - 4 months ago

LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

May 7, 2025, 6:00 AM EDT - 4 months ago

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

May 7, 2025, 5:45 AM EDT - 4 months ago

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova to Announce First-Quarter 2025 Results

Mar 26, 2025, 8:00 AM EDT - 6 months ago

LivaNova to Announce First-Quarter 2025 Results

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:10 PM EST - 7 months ago

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

Feb 25, 2025, 6:00 AM EST - 7 months ago

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Present at the Barclays Global Healthcare Conference

Feb 21, 2025, 9:00 AM EST - 7 months ago

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

Jan 21, 2025, 9:00 AM EST - 8 months ago

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Dec 18, 2024, 8:30 AM EST - 9 months ago

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

Dec 5, 2024, 9:00 AM EST - 10 months ago

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

Nov 14, 2024, 9:00 AM EST - 11 months ago

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Nov 11, 2024, 4:05 PM EST - 11 months ago

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 2:30 PM EDT - 11 months ago

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

LivaNova Reports Third-Quarter 2024 Results

Oct 30, 2024, 6:00 AM EDT - 11 months ago

LivaNova Reports Third-Quarter 2024 Results

LivaNova: Economics Should Start Making Sustained Improvements

Oct 18, 2024, 3:45 AM EDT - 1 year ago

LivaNova: Economics Should Start Making Sustained Improvements

LivaNova Appoints Susan Podlogar as a New Director

Oct 8, 2024, 9:00 AM EDT - 1 year ago

LivaNova Appoints Susan Podlogar as a New Director

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

Oct 4, 2024, 11:59 AM EDT - 1 year ago

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

LivaNova to Announce Third-Quarter 2024 Results

Sep 25, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce Third-Quarter 2024 Results

LivaNova to Present at the Baird Global Healthcare Conference

Aug 19, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Present at the Baird Global Healthcare Conference

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 1:57 PM EDT - 1 year ago

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

LivaNova Reports Second-Quarter 2024 Results

Jul 31, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports Second-Quarter 2024 Results

Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach

Jun 24, 2024, 6:24 PM EDT - 1 year ago

Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach

LivaNova to Announce Second-Quarter 2024 Results

Jun 18, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce Second-Quarter 2024 Results

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

Jun 6, 2024, 9:00 AM EDT - 1 year ago

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

LivaNova to Present at the Goldman Sachs Healthcare Conference

May 23, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Present at the Goldman Sachs Healthcare Conference

LivaNova PLC (LIVN) Q1 2024 Earnings Call Transcript

May 1, 2024, 10:56 AM EDT - 1 year ago

LivaNova PLC (LIVN) Q1 2024 Earnings Call Transcript

LivaNova Reports First-Quarter 2024 Results

May 1, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports First-Quarter 2024 Results

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

Apr 30, 2024, 9:00 AM EDT - 1 year ago

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident

Apr 25, 2024, 4:03 PM EDT - 1 year ago

LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident

LivaNova to Announce First-Quarter 2024 Results

Mar 21, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce First-Quarter 2024 Results

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Mar 20, 2024, 9:00 AM EDT - 1 year ago

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

Mar 5, 2024, 9:55 PM EST - 1 year ago

LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

Mar 4, 2024, 4:44 PM EST - 1 year ago

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

LivaNova PLC (LIVN) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 10:36 AM EST - 1 year ago

LivaNova PLC (LIVN) Q4 2023 Earnings Call Transcript

LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

Feb 21, 2024, 6:00 AM EST - 1 year ago

LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

healthcareguru
healthcareguru Sep. 16 at 7:35 PM
$LIVN back to $50 👎
0 · Reply
THE_Perfusionist
THE_Perfusionist Sep. 12 at 9:36 PM
$IINN $LIVN has them beat along with other Huge player like $MDT https://www.livanova.com/cardiopulmonary/en-us/essenz/in-line-blood-monitor https://www.medtronic.com/en-us/healthcare-professionals/products/cardiovascular/extracorporeal-membrane-oxygenation/nautilus-smart-ecmo-oxygenator-module.html This disposable ECMO oxy has this tech built in! This is where the ECMO space is going. Not standalone devices.
3 · Reply
Mogeyman
Mogeyman Sep. 9 at 7:56 PM
$LIVN
0 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 12:00 PM
Needham has updated their rating for LivaNova ( $LIVN ) to Buy with a price target of 64.
0 · Reply
Mogeyman
Mogeyman Sep. 3 at 10:44 AM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 28 at 11:34 AM
$LIVN
0 · Reply
healthcareguru
healthcareguru Aug. 27 at 12:19 AM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 26 at 7:25 PM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 25 at 4:51 PM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 22 at 8:20 PM
$LIVN
0 · Reply
topstockalerts
topstockalerts Aug. 21 at 3:14 PM
$LIVN & it’s green..
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 21 at 2:47 PM
$LIVN Barclays Maintains Equal-Weight on LivaNova, Raises Price Target to $58
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 2:46 PM
Barclays updates rating for LivaNova ( $LIVN ) to Equal-Weight, target set at 55 → 58.
0 · Reply
Mogeyman
Mogeyman Aug. 21 at 2:27 PM
$LIVN
0 · Reply
Mogeyman
Mogeyman Aug. 20 at 12:59 AM
$LIVN Just chugging along. Get ready for big 4Q.
0 · Reply
Estimize
Estimize Aug. 6 at 10:06 PM
$LIVN reported 1.05 EPS and 352.50 revenue for Q2. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm
0 · Reply
MaverikIT
MaverikIT Aug. 6 at 1:50 PM
@rxptgh @Thelonius_Stonk $LIVN +5.13 Delivered double-digit reported and organic revenue growth and continued operating margin expansion Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1)
0 · Reply
DonCorleone77
DonCorleone77 Aug. 6 at 10:27 AM
$LIVN LivaNova reports Q2 adjusted EPS $1.05, consensus 87c -- Q2 revenue $352.5M, consensus $332.21M. -- Raises FY25 adjusted EPS view to $3.70-$3.80 from $3.60-$3.70, consensus $3.65.
1 · Reply
keypatience
keypatience Aug. 1 at 8:21 PM
$IOVA $XBI $LIVN $URGN $ADAP This dude is the biggest dummy on Stocktwits.
3 · Reply
Mogeyman
Mogeyman Aug. 1 at 2:45 PM
$LIVN
0 · Reply
Mogeyman
Mogeyman Jul. 31 at 8:54 PM
$LIVN
0 · Reply
Mogeyman
Mogeyman Jul. 30 at 4:21 PM
$LIVN
0 · Reply